Literature DB >> 28833542

Echo-planar spectroscopic imaging with dual-readout alternated gradients (DRAG-EPSI) at 7 T: Application for 2-hydroxyglutarate imaging in glioma patients.

Zhongxu An1, Vivek Tiwari1, Sandeep K Ganji1, Jeannie Baxter1, Michael Levy2, Marco C Pinho1,3, Edward Pan2,4,5, Elizabeth A Maher4,5,6,7, Toral R Patel2,4, Bruce E Mickey2,5,7, Changho Choi1,3,5.   

Abstract

PURPOSE: To develop echo-planar spectroscopic imaging (EPSI) with large spectral width and accomplish high-resolution imaging of 2-hydroxyglutarate (2HG) at 7 T.
METHODS: We designed a new EPSI readout scheme at 7 T. Data were recorded with dual-readout alternated gradients and combined according to the gradient polarity. Following validation of its performance in phantoms, the new readout scheme, together with previously reported 2HG-optimized magnetic resonance spectroscopy (point-resolved spectroscopy echo time of 78 ms), was used for time-efficient and high-resolution imaging of 2HG and other metabolites in five glioma patients before treatment. Unsuppressed water, acquired with EPSI, was used as reference for multichannel combination, eddy-current compensation, and metabolite quantification. Spectral fitting was conducted with the LCModel using in-house calculated basis sets.
RESULTS: Using a readout gradient strength of 9.5 mT/m and slew rate of 90 mT/m/ms, dual-readout alternated gradients EPSI permitted 1638-Hz spectral width with 6 × 6 mm2 in-plane resolution at 7 T. Phantom data indicated that dual-readout alternated gradients EPSI provides proper metabolite signals and induces much less frequency drifts than conventional EPSI. For a spatial resolution of 0.5 mL, 2HG was detected in tumors with precision (Cramer-Rao lower bound < 10%). The 2HG was estimated to be 2.3 to 3.3 mM in tumors of three patients with biopsy-proven isocitrate dehydrogenase (IDH) mutant gliomas. The 2HG was undetectable in an IDH wild-type glioblastoma. For a radiographically suggested glioma, the estimated 2HG of 2.3 ± 0.2 mM (Cramer-Rao lower bound < 10%) indicated that the lesion may be an IDH mutant glioma.
CONCLUSIONS: The data indicated that the dual-readout alternated gradients EPSI can provide reliable high-resolution imaging of 2HG in glioma patients at 7 T in vivo. Magn Reson Med 79:1851-1861, 2018.
© 2017 International Society for Magnetic Resonance in Medicine. © 2017 International Society for Magnetic Resonance in Medicine.

Entities:  

Keywords:  1H MRS; 2-hydroxyglutarate (2HG); 7T; dual-readout alternated-gradients EPSI (DRAG-EPSI); echo-planar spectroscopy imaging (EPSI); glioma; human brain tumor

Mesh:

Substances:

Year:  2017        PMID: 28833542      PMCID: PMC5811378          DOI: 10.1002/mrm.26884

Source DB:  PubMed          Journal:  Magn Reson Med        ISSN: 0740-3194            Impact factor:   4.668


  35 in total

1.  Detection and correction of frequency instabilities for volumetric 1H echo-planar spectroscopic imaging.

Authors:  Andreas Ebel; Andrew A Maudsley
Journal:  Magn Reson Med       Date:  2005-02       Impact factor: 4.668

2.  High speed 1H spectroscopic imaging in human brain by echo planar spatial-spectral encoding.

Authors:  S Posse; G Tedeschi; R Risinger; R Ogg; D Le Bihan
Journal:  Magn Reson Med       Date:  1995-01       Impact factor: 4.668

3.  Prospective Longitudinal Analysis of 2-Hydroxyglutarate Magnetic Resonance Spectroscopy Identifies Broad Clinical Utility for the Management of Patients With IDH-Mutant Glioma.

Authors:  Changho Choi; Jack M Raisanen; Sandeep K Ganji; Song Zhang; Sarah S McNeil; Zhongxu An; Akshay Madan; Kimmo J Hatanpaa; Vamsidhara Vemireddy; Christie A Sheppard; Dwight Oliver; Keith M Hulsey; Vivek Tiwari; Tomoyuki Mashimo; James Battiste; Samuel Barnett; Christopher J Madden; Toral R Patel; Edward Pan; Craig R Malloy; Bruce E Mickey; Robert M Bachoo; Elizabeth A Maher
Journal:  J Clin Oncol       Date:  2016-10-31       Impact factor: 44.544

4.  Mapping of glycine distributions in gliomas.

Authors:  A A Maudsley; R K Gupta; R Stoyanova; N A Parra; B Roy; S Sheriff; N Hussain; S Behari
Journal:  AJNR Am J Neuroradiol       Date:  2014-01-30       Impact factor: 3.825

5.  Signal-to-noise ratio and spectral linewidth improvements between 1.5 and 7 Tesla in proton echo-planar spectroscopic imaging.

Authors:  Ricardo Otazo; Bryon Mueller; Kamil Ugurbil; Lawrence Wald; Stefan Posse
Journal:  Magn Reson Med       Date:  2006-12       Impact factor: 4.668

6.  Releasing the block: setting differentiation free with mutant IDH inhibitors.

Authors:  Christopher J Pirozzi; Zachary J Reitman; Hai Yan
Journal:  Cancer Cell       Date:  2013-05-13       Impact factor: 31.743

7.  An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.

Authors:  Dan Rohle; Janeta Popovici-Muller; Nicolaos Palaskas; Sevin Turcan; Christian Grommes; Carl Campos; Jennifer Tsoi; Owen Clark; Barbara Oldrini; Evangelia Komisopoulou; Kaiko Kunii; Alicia Pedraza; Stefanie Schalm; Lee Silverman; Alexandra Miller; Fang Wang; Hua Yang; Yue Chen; Andrew Kernytsky; Marc K Rosenblum; Wei Liu; Scott A Biller; Shinsan M Su; Cameron W Brennan; Timothy A Chan; Thomas G Graeber; Katharine E Yen; Ingo K Mellinghoff
Journal:  Science       Date:  2013-04-04       Impact factor: 47.728

8.  An integrated genomic analysis of human glioblastoma multiforme.

Authors:  D Williams Parsons; Siân Jones; Xiaosong Zhang; Jimmy Cheng-Ho Lin; Rebecca J Leary; Philipp Angenendt; Parminder Mankoo; Hannah Carter; I-Mei Siu; Gary L Gallia; Alessandro Olivi; Roger McLendon; B Ahmed Rasheed; Stephen Keir; Tatiana Nikolskaya; Yuri Nikolsky; Dana A Busam; Hanna Tekleab; Luis A Diaz; James Hartigan; Doug R Smith; Robert L Strausberg; Suely Kazue Nagahashi Marie; Sueli Mieko Oba Shinjo; Hai Yan; Gregory J Riggins; Darell D Bigner; Rachel Karchin; Nick Papadopoulos; Giovanni Parmigiani; Bert Vogelstein; Victor E Velculescu; Kenneth W Kinzler
Journal:  Science       Date:  2008-09-04       Impact factor: 47.728

9.  2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas.

Authors:  Changho Choi; Sandeep K Ganji; Ralph J DeBerardinis; Kimmo J Hatanpaa; Dinesh Rakheja; Zoltan Kovacs; Xiao-Li Yang; Tomoyuki Mashimo; Jack M Raisanen; Isaac Marin-Valencia; Juan M Pascual; Christopher J Madden; Bruce E Mickey; Craig R Malloy; Robert M Bachoo; Elizabeth A Maher
Journal:  Nat Med       Date:  2012-01-26       Impact factor: 53.440

10.  The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.

Authors:  Patrick S Ward; Jay Patel; David R Wise; Omar Abdel-Wahab; Bryson D Bennett; Hilary A Coller; Justin R Cross; Valeria R Fantin; Cyrus V Hedvat; Alexander E Perl; Joshua D Rabinowitz; Martin Carroll; Shinsan M Su; Kim A Sharp; Ross L Levine; Craig B Thompson
Journal:  Cancer Cell       Date:  2010-02-18       Impact factor: 38.585

View more
  15 in total

1.  Combining multiband slice selection with consistent k-t-space EPSI for accelerated spectral imaging.

Authors:  Rita Schmidt; Amir Seginer; Assaf Tal
Journal:  Magn Reson Med       Date:  2019-04-16       Impact factor: 4.668

Review 2.  Application of 7T MRS to High-Grade Gliomas.

Authors:  L McCarthy; G Verma; G Hangel; A Neal; B A Moffat; J P Stockmann; O C Andronesi; P Balchandani; C G Hadjipanayis
Journal:  AJNR Am J Neuroradiol       Date:  2022-05-26       Impact factor: 4.966

3.  3D high-resolution imaging of 2-hydroxyglutarate in glioma patients using DRAG-EPSI at 3T in vivo.

Authors:  Zhongxu An; Vivek Tiwari; Jeannie Baxter; Michael Levy; Kimmo J Hatanpaa; Edward Pan; Elizabeth A Maher; Toral R Patel; Bruce E Mickey; Changho Choi
Journal:  Magn Reson Med       Date:  2018-09-14       Impact factor: 4.668

4.  In vivo 2-hydroxyglutarate-proton magnetic resonance spectroscopy (3 T, PRESS technique) in treatment-naïve suspect lower-grade gliomas: feasibility and accuracy in a clinical setting.

Authors:  Valeria Cuccarini; Luigi Antelmi; Bianca Pollo; Rosina Paterra; Chiara Calatozzolo; Anna Nigri; Francesco DiMeco; Marica Eoli; Gaetano Finocchiaro; Greta Brenna; Irene Tramacere; Maria Grazia Bruzzone; Elena Anghileri
Journal:  Neurol Sci       Date:  2019-10-24       Impact factor: 3.307

5.  In vivo MRS measurement of 2-hydroxyglutarate in patient-derived IDH-mutant xenograft mouse models versus glioma patients.

Authors:  Vivek Tiwari; Tomoyuki Mashimo; Zhongxu An; Vamsidhara Vemireddy; Sara Piccirillo; Pegah Askari; Keith M Hulsey; Shanrong Zhang; Robin A de Graaf; Toral R Patel; Edward Pan; Bruce E Mickey; Elizabeth A Maher; Robert M Bachoo; Changho Choi
Journal:  Magn Reson Med       Date:  2020-01-30       Impact factor: 4.668

6.  2-Hydroxyglutarate MR spectroscopy for prediction of isocitrate dehydrogenase mutant glioma: a systemic review and meta-analysis using individual patient data.

Authors:  Chong Hyun Suh; Ho Sung Kim; Seung Chai Jung; Choong Gon Choi; Sang Joon Kim
Journal:  Neuro Oncol       Date:  2018-11-12       Impact factor: 13.029

7.  Ultra-High-Field MRI in the Diagnosis and Management of Gliomas: A Systematic Review.

Authors:  Annabelle Shaffer; Susanna S Kwok; Anant Naik; Aaron T Anderson; Fan Lam; Tracey Wszalek; Paul M Arnold; Wael Hassaneen
Journal:  Front Neurol       Date:  2022-04-05       Impact factor: 4.003

Review 8.  Accelerated MR spectroscopic imaging-a review of current and emerging techniques.

Authors:  Wolfgang Bogner; Ricardo Otazo; Anke Henning
Journal:  NMR Biomed       Date:  2020-05-12       Impact factor: 4.044

9.  Mutant IDH1 gliomas downregulate phosphocholine and phosphoethanolamine synthesis in a 2-hydroxyglutarate-dependent manner.

Authors:  Pavithra Viswanath; Marina Radoul; Jose Luis Izquierdo-Garcia; Hema Artee Luchman; J Gregory Cairncross; Russell O Pieper; Joanna J Phillips; Sabrina M Ronen
Journal:  Cancer Metab       Date:  2018-04-03

10.  Whole-Slab 3D MR Spectroscopic Imaging of the Human Brain With Spiral-Out-In Sampling at 7T.

Authors:  Morteza Esmaeili; Bernhard Strasser; Wolfgang Bogner; Philipp Moser; Zhe Wang; Ovidiu C Andronesi
Journal:  J Magn Reson Imaging       Date:  2020-11-12       Impact factor: 5.119

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.